Used in targeted cancer immunotherapy, this antibody specifically binds to Claudin-6 (CLDN6), a protein overexpressed in various solid tumors but largely absent in healthy tissues. Its high specificity enables precise targeting of tumor cells, making it a valuable tool in the development of antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies. It has shown promise in preclinical studies for treating cancers such as testicular, ovarian, and pediatric malignancies. Additionally, it serves as a reference standard in assay development, target validation, and therapeutic antibody screening.